Latest Breaking News On - Arbutus biopharma corporation nasdaq - Page 6 : comparemela.com

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase .

United statesNew zealandLisam caperelliMelissav rewolinskiN acetylgalactosamine galnacWilliam collierElizabeth howardKaren simsWorld health organizationDrug administrationSecurities exchangeArbutus biopharma corporation nasdaqClinical developmentRoivant sciences ltdDevice safety authority medsafeInstitute for health metrics

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 20, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target.

Lisam caperelliArbutus biopharma corporation nasdaqBiopharma corporation

Arbutus Appoints Melissa V Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target.

United statesWilliam collierLisam caperelliMelissav rewolinskiChemical development group leaderRice universitySecurities exchangeDevelopment for amira pharmaceuticalsLannett company incArbutus biopharma corporation nasdaqBiopharma corporationArbutus boardChief executive officerSenior vice presidentTechnical operationsSenior director

Arbutus Biopharma (ABUS) Appoints Melissa V Rewolinski to its Board

Arbutus Biopharma (ABUS) Appoints Melissa V Rewolinski to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWilliam collierMelissav rewolinskiDevelopment for amira pharmaceuticalsChemical development group leaderRice universityArbutus biopharma corporation nasdaqLannett company incArbutus biopharma corporationArbutus boardChief executive officerSenior vice presidentTechnical operationsSenior directorAmira pharmaceuticalsPharmaceutical sciences project team leader

Arbutus Appoints Two New Executives

Arbutus Appoints Two New Executives
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity collegeNew south walesKaren simsLisam caperelliChristopher naftzgerWilliam collierElizabeth howardClinical developmentUniversity of pennsylvania school medicineKoch industriesBlank romeArbutus biopharma corporation nasdaqSecurities exchangeWorld health organizationUniversity of pennsylvania